Passive immunization utilizing anti-PCSK9 antibodies, including alirocumab and evolocumab, has demonstrated notable efficacy in decreasing LDL-C levels and ameliorating cardiovascular disease. This evidence concerns the gene PCSK9 and cardiovascular disorder.